Return to homepagePandemic Pact

Identifying mechanisms of transformation and novel strategies to prevent evolution of TP53 mutant AML

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA409725

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2025
    2028

  • Known Financial Commitments (USD)

    $109,067.48

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    The Walter and Eliza Hall Institute of Medical Research

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Acute myeloid leukaemia is an aggressive blood cancer with poor survival. Even with the available arsenal of treatments, many patients still succumb to relapse and death. Building on the successes of COVID-19 vaccine technology, our lab aims to develop a cancer vaccine that harnesses the power of the immune system to target and eradicate leukaemic cells. We will test this vaccine in genetically engineered mice before progressing to clinical trials. Our approach may also benefit other cancers.